drugset / Trial / NCT02311413
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
Phase 2
Completed
39 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Circassia Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).
Timeline
- Start
- 2015-03-09
- Primary completion
- 2018-07-18
- Completion
- 2018-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cat-PAD | Peptide | — | Other |
Indications
No indication recorded.